Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism

A Randomized Controlled Trial Study of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Acute Dystonia or Parkinsonism

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00331825

Enrollment

Registered

2006-05-31

Start date

2000-07-31

Completion date

2003-07-31

Last updated

2006-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extrapyramidal Syndrome, Schizophrenia

Keywords

Schizophrenia, EPS, risperidone, olanzapine

Brief summary

We initiate a study with research grant from department of health and Taoyuan mental hospital and choose risperidone and olanzapine as study medications. We compare the incidence of using anticholinergic drugs in schizophrenic patients of Han ethnics with neuroleptic-induced acute dystonia or parkinsonism to test the hypothesis that these two medications have different EPS incidence in EPS intolerant population.

Detailed description

Objective: First generation antipsychotics frequently induced extrapyramidal side effects (EPS). Second generation antipsychotics were the choices for EPS intolerant schizophrenic patients. But which one of second generation antipsychotic was the better choice did not have definitive results. We compared risperidone and olanzapine in schizophrenic patients with acute dystonia or parkinsonism side effects and observed the incidence of needing concomitant anticholinergic drugs. We also collected the data of average dose of risperidone and olanzapine to help the dosing strategy guidelines for EPS intolerant schizophrenic patients. Method: This randomized, rater-blind, parallel group, flexible dose study enrolled patients from Taoyuan Mental Hospital from July 2000 to July 2003. Schizophrenia (DSM-IV) patients who met the research criteria of neuroleptic-induced acute dystonia or parkinsonism research criteria of DSM-IV and greater than moderate severity (\>4) of global impression of extrapyramidal syndrome rating scale (ESRS). 70 patients were random assignment to risperidone or olanzapine for 8 weeks. The primary outcome was to compare the incidence of concomitant anticholinergic drugs.

Interventions

DRUGRisperidone and Olanzapine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Age of 18-65 y/o; * Female patients did not have pregnancy plans and must agree to use reliable pregnancy prevention methods if during childbearing age; * Meet schizophrenia criteria of DSM-IV; * Fulfill DSM-IV neuroleptic-induced acute dystonia or parkinsonism research criteria, the severity of acute dystonia or parkinsonism was greater than moderate degree (\>4) assessed by global impression of Extrapyramidal System Rating Scale (item 43 and 44 of ESRS); * Patients or legal responsible people agree to join study and sign informed consent

Exclusion criteria

* Had other axis I diagnosis of DSM-IV; * Unstable major systemic diseases; * Had neurological disorder influenced to EPS assessment; * Substance abuse or dependence other then coffee or tobacco within 6 months before study

Design outcomes

Primary

Measure	Time frame
Percentage of using concomitant anticholinergic drugs	—

Secondary

Measure	Time frame
Scores of Rating Scale (Extrapyramidal System Rating Scale, Brief Psychiatric Rating Scale)	—

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026